Sophie D. G.
- Country
- France
- Department
- Hematology
Research Overview
- Efficacy and Safety Comparison of Obinutuzumab-Venetoclax vs. Obinutuzumab-Chlorambucil in Untreated CLL with Comorbidities
- Phase 3 Randomized Study of Pirtobrutinib, Venetoclax, and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Phase III Multicenter Study on Safety, Pharmacokinetics, and Efficacy of Crovalimab vs. Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients on Complement Inhibitors
Data & Insights
Has run more than one trial at 153 of 315 partner sites.
Specializations
Chronic Lymphocytic Leukemia Research
The investigator specializes in treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), with particular focus on novel therapeutic approaches for both treatment-naïve and previously treated patients.
- BTK Inhibitor Therapies
- Venetoclax-Based Combinations
- MRD-Guided Treatment Strategies
Expertise includes evaluation of targeted therapies and development of personalized treatment approaches for elderly patients with CLL/SLL.
Lymphoma Studies
Active involvement in research focusing on mantle cell lymphoma (MCL) and Richter's syndrome, investigating novel combination therapies and treatment protocols.
- Chemoimmunotherapy Combinations
- Bispecific Antibody Treatments
- Transformation Studies
Specialized focus on treating high-grade lymphoma transformations and innovative therapeutic combinations.
Rare Blood Disorders
Research expertise extends to rare hematologic conditions, particularly paroxysmal nocturnal hemoglobinuria (PNH), evaluating novel complement inhibitor therapies.
- Complement Inhibition Studies
- Novel Therapeutic Approaches
- Safety and Efficacy Evaluations
Focus on developing and assessing innovative treatment options for patients with rare blood disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.